← Back to patent-cliff list
Ganciclovir ophthalmic gel (Laboratoires Thea)
Tier C — Watch / tradeGanciclovir ophthalmic gel (Laboratoires Thea)
Laboratoires Théa, France
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：UL30
Brand：Zirgan, Virgan
Indications (approved)：疱疹性角膜炎, 病毒性眼感染
Regional status
US
Approved
2009-09-15
EU
Approved
2000-07-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ganciclovir ophthalmic gel (Laboratoires Thea)?
Approved indications include: 疱疹性角膜炎, 病毒性眼感染.
When does the Ganciclovir ophthalmic gel (Laboratoires Thea) patent expire?
No public expiry year is available for Ganciclovir ophthalmic gel (Laboratoires Thea) yet; this page updates once verified.
How do I get a quote for Ganciclovir ophthalmic gel (Laboratoires Thea) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27